Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Veeda Clinical Research Ltd. on July 3, 2025. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Veeda Clinical Research Ltd. IPO is a Book Build Issue consisting of fresh issue of ₹185.00 crores and an offer for sale (OFS) of upto 1.30 crore equity shares.
The equity shares are proposed to be listed on NSE and BSE. Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Veeda Clinical Research IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹2 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Fresh Issue | [.] shares (agg. up to ₹185 Cr) |
| Offer for Sale | 1,30,08,128 shares of ₹2 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 6,57,77,495 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Feb 7, 2025 |
| SEBI/Exchange approval received | Thu, Jul 3, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not More than 75% of the Net Offer |
| Retail Shares Offered | Not more than 10% of the Net Offer |
| NII Shares Offered | Not more than 15% of the Net Offer |
Founded in April 2004, Veeda Clinical Research Limited is a full-service contract research organization (CRO) providing a comprehensive range of services in drug development, including non-clinical, pre-clinical, bioavailability, bioequivalence studies, and clinical trials for various drugs such as novel entities, generics, and biosimilars, as well as medical devices.
The company's services include the following.
As of September 30, 2024, the company completed 119 global regulatory inspections in HVS and Pre-Clinical services by authorities including the FDA, UK-MHRA, WHO, ANVISA, DCGI, EMA, and NPRA.
As of September 30, 2024, the company has over 436 active clients worldwide.
The company has successfully conducted studies for 417, 504, 498, and 580 clients during the six months ending September 30, 2024, and for the financial years 2024, 2023, and 2022, respectively.
As of September 2024, the company employs 914 people in various departments.
Competitive Strengths:
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 1,891.86 | 2,040.21 | 734.77 | 677.54 |
| Total Income | 315.87 | 407.99 | 420.21 | 293.11 |
| Profit After Tax | -24.93 | -0.36 | 42.42 | 50.46 |
| NET Worth | 1,192.51 | 1,190.96 | 564.90 | 503.21 |
| Reserves and Surplus | 1,048.91 | 1,047.37 | 446.58 | 419.58 |
| Total Borrowing | 405.49 | 261.69 | 48.57 | 47.20 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital expenditure towards procurement of equipment and machinery | 50.00 |
| 2 | Investment in our Material Subsidiary, Bioneeds India Private Limited for capital expenditure towards procurement of equipment and machinery | 35.00 |
| 3 | Investment in our Material Subsidiary, Bioneeds India Pvt.Ltd. for Repayment/pre-payment, in part or full of certain borrowings of Bioneeds India Pvt.Ltd. | 10.89 |
| 4 | Funding organic growth of Company, our Material Subsidiary, Bioneeds India Pvt.Ltd. and Health Data Specialists (Holdings) Ltd. through marketing and promotional activities, updation of technology and adoption of modern digital solutions in workflows to enhance the efficiency and quality assurance of our operating processes and data management | 33.00 |
| 5 | General corporate purposes | |
| Total | 128.89 |
| KPI | Mar 31, 2023 |
|---|---|
| Debt/Equity | 0.32 |
| RoNW | -0.02% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 33.83% |
Veeda Clinical Research IPO is a main-board IPO of 0 equity shares of the face value of ₹2 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Veeda Clinical Research IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Veeda Clinical Research IPO using UPI as a payment gateway. Zerodha customers can apply in Veeda Clinical Research IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Veeda Clinical Research IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Veeda Clinical Research IPO dates are not announced. Please check back again after some time.
Veeda Clinical Research IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Veeda Clinical Research IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Veeda Clinical Research IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Veeda Clinical Research IPO allotment status.
The Veeda Clinical Research IPO listing date is not yet announced. The tentative date of listing is .
